Clinical management of rivaroxaban-treated patients
暂无分享,去创建一个
W. Ageno | G. Palareti | A. Rubboli | D. Toni | D. Imberti | A. Ferrari | V. Pengo | A. Filippi
[1] R. Haynes,et al. Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.
[2] E. Roth,et al. Physical Activity and Exercise Recommendations for Stroke Survivors A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. , 2014 .
[3] F. García-Bragado Dalmau. [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.
[4] K. Butcher,et al. Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal , 2012, Stroke.
[5] J. Cracowski,et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.
[6] J. Strobeck. Stroke Prevention in Atrial Fibrillation: Managing the Risks in Light of New Oral Anticoagulants , 2012, Cardiovascular Drugs and Therapy.
[7] W. Dzik. Reversal of drug‐induced anticoagulation: old solutions and new problems , 2012, Transfusion.
[8] K. Bauer. Reversal of antithrombotic agents , 2012, American journal of hematology.
[9] J. Douketis,et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors , 2012, American journal of hematology.
[10] G. Raskob,et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.
[11] G. Breithardt,et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF , 2012, The Lancet Neurology.
[12] S. Schulman,et al. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. , 2012, Blood.
[13] J. Harenberg,et al. Determination of Rivaroxaban in Human Plasma Samples , 2012, Seminars in Thrombosis & Hemostasis.
[14] Mark Crowther,et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[15] G. Lip,et al. Stroke prevention in atrial fibrillation: do we still need warfarin? , 2012, Current opinion in neurology.
[16] Paul Burton,et al. Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[17] W. Ageno,et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis , 2012 .
[18] A. Rubboli. The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update , 2012, Internal and Emergency Medicine.
[19] P. Kamphuisen,et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.
[20] A. Tosetto,et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). , 2011, Thrombosis and haemostasis.
[21] P. Kamphuisen,et al. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents , 2011, Journal of thrombosis and haemostasis : JTH.
[22] C. Weiss,et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability , 2011, Journal of Thrombosis and Thrombolysis.
[23] Marie T. Brown,et al. Medication adherence: WHO cares? , 2011, Mayo Clinic proceedings.
[24] A. Tripodi,et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro study , 2011, Journal of thrombosis and haemostasis : JTH.
[25] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[26] R. Gans,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.
[27] R. Stafford,et al. Safety of recombinant activated factor VII in randomized clinical trials. , 2011, The New England journal of medicine.
[28] F. Haddad,et al. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. , 2011, The Journal of bone and joint surgery. British volume.
[29] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[30] H. Bruck,et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2010, British journal of clinical pharmacology.
[31] P. Perel,et al. Tranexamic acid for trauma – Authors' reply , 2010, The Lancet.
[32] Fredrik Folke,et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.
[33] F. Depasse,et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma , 2010, Thrombosis and Haemostasis.
[34] A. McDonald,et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial , 2010, The Lancet.
[35] M. Girardis,et al. Posttraumatic massive bleeding: a challenging multidisciplinary task , 2010, Internal and emergency medicine.
[36] Elisabeth Perzborn,et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor , 2010, Thrombosis and Haemostasis.
[37] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[38] P. Kamphuisen,et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. , 2010, The Netherlands journal of medicine.
[39] P. Kirchhof,et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.
[40] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[41] M. Crowther,et al. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents , 2009, Journal of thrombosis and haemostasis : JTH.
[42] S. Iliceto,et al. Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery: An Inception Cohort Management Study , 2009, Circulation.
[43] M. Gent,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial , 2009, The Lancet.
[44] Wi-Sun Ryu,et al. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage , 2009, Neurology.
[45] Mahendra Patel,et al. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .
[46] Bengt I Eriksson,et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.
[47] W. Ageno,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.
[48] B. Eriksson,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.
[49] M. Crowther,et al. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. , 2008, Blood.
[50] C. Sosnowski. [Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15]. , 2008, Kardiologia polska.
[51] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[52] D. Kubitza,et al. Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity 1 , 2007, Journal of clinical pharmacology.
[53] N. Rosencher,et al. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies , 2007, Anaesthesia.
[54] P. Mannucci,et al. Prevention and treatment of major blood loss. , 2007, The New England journal of medicine.
[55] C. Négrier,et al. Coagulation factor concentrates: past, present, and future , 2007, The Lancet.
[56] P. Mannucci,et al. Drug therapy: Prevention and treatment of major blood loss , 2007 .
[57] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[58] D. Kubitza,et al. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases , 2006, Expert opinion on investigational drugs.
[59] Eric E. Smith,et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke , 2002, Neurology.
[60] S. Ibbotson,et al. The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro , 1991, Thrombosis and Haemostasis.
[61] L Goldman,et al. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.